Parkman Healthcare Partners LLC Cuts Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Parkman Healthcare Partners LLC reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 41.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 37,472 shares of the biotechnology company's stock after selling 26,559 shares during the period. United Therapeutics comprises 1.8% of Parkman Healthcare Partners LLC's investment portfolio, making the stock its 19th biggest position. Parkman Healthcare Partners LLC owned approximately 0.08% of United Therapeutics worth $13,222,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in UTHR. Man Group plc grew its holdings in shares of United Therapeutics by 0.7% in the fourth quarter. Man Group plc now owns 46,723 shares of the biotechnology company's stock worth $16,486,000 after purchasing an additional 302 shares during the last quarter. Nissay Asset Management Corp Japan ADV boosted its stake in United Therapeutics by 1.2% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 5,192 shares of the biotechnology company's stock valued at $1,869,000 after buying an additional 61 shares during the last quarter. Nomura Holdings Inc. bought a new position in United Therapeutics during the 4th quarter valued at about $2,090,000. Mubadala Investment Co PJSC purchased a new stake in shares of United Therapeutics in the 4th quarter worth $2,386,000. Finally, NDVR Inc. boosted its stake in United Therapeutics by 11.4% in the fourth quarter. NDVR Inc. now owns 644 shares of the biotechnology company's stock valued at $227,000 after acquiring an additional 66 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $308.07 on Wednesday. United Therapeutics Co. has a 1 year low of $264.33 and a 1 year high of $417.82. The company has a 50-day moving average price of $300.54 and a 200-day moving average price of $341.52. The stock has a market capitalization of $13.90 billion, a P/E ratio of 13.53, a P/E/G ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. During the same quarter in the previous year, the firm posted $6.17 EPS. The business's revenue for the quarter was up 17.2% compared to the same quarter last year. As a group, equities research analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the subject of several recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a report on Monday, May 5th. Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price target for the company in a report on Monday, April 21st. JPMorgan Chase & Co. lowered their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. Wells Fargo & Company reiterated an "equal weight" rating and issued a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Finally, StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $392.00.

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $300.93, for a total transaction of $3,310,230.00. Following the sale, the executive vice president now directly owns 36,781 shares of the company's stock, valued at $11,068,506.33. This represents a 23.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $956,195.85. This represents a 79.51% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 65,500 shares of company stock valued at $20,765,280. Company insiders own 11.90% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.